CY2017028I1 - 3-{(3R,4R)-4-ΜΕΘΥΛ-3-[ΜΕΘΥΛ-(7Η-ΠΥΡΡΟΛΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-4-ΥΛ)-ΑΜΙΝΟ]-ΠΙΠΕΡΙΔΙΝΥΛ}-3-ΟΞΟ-ΠΡΟΠΙΟΝΙΤΡΙΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΩΝ ΠΡΩΤΕΪΝΗΣ - Google Patents

3-{(3R,4R)-4-ΜΕΘΥΛ-3-[ΜΕΘΥΛ-(7Η-ΠΥΡΡΟΛΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-4-ΥΛ)-ΑΜΙΝΟ]-ΠΙΠΕΡΙΔΙΝΥΛ}-3-ΟΞΟ-ΠΡΟΠΙΟΝΙΤΡΙΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΩΝ ΠΡΩΤΕΪΝΗΣ

Info

Publication number: CY2017028I1
Authority: CY; Cyprus
Prior art keywords: methyl; propionitrile; pyrrolo; pyrimidin; piperidinyl
Prior art date: 2001-05-31

Application number

CY2017028C

Other languages

English (en)

Other versions

CY2017028I2 (el

Original Assignee

Pfizer Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-31

Filing date

2017-09-01

Publication date

2018-02-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2017028(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-09-01 Application filed by Pfizer Limited filed Critical Pfizer Limited

2018-02-14 Publication of CY2017028I2 publication Critical patent/CY2017028I2/el

2018-02-14 Publication of CY2017028I1 publication Critical patent/CY2017028I1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY2017028C 2001-05-31 2017-09-01 3-{(3R,4R)-4-ΜΕΘΥΛ-3-[ΜΕΘΥΛ-(7Η-ΠΥΡΡΟΛΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-4-ΥΛ)-ΑΜΙΝΟ]-ΠΙΠΕΡΙΔΙΝΥΛ}-3-ΟΞΟ-ΠΡΟΠΙΟΝΙΤΡΙΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΩΝ ΠΡΩΤΕΪΝΗΣ CY2017028I1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29477501P	2001-05-31	2001-05-31
US34104801P	2001-12-06	2001-12-06
EP02733058A EP1392694A1 (en)	2001-05-31	2002-05-29	Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors

Publications (2)

Publication Number	Publication Date
CY2017028I2 CY2017028I2 (el)	2018-02-14
CY2017028I1 true CY2017028I1 (el)	2018-02-14

Family

ID=26968730

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20121101069T CY1113322T1 (el)	2001-05-31	2012-11-09	3-{(3R,4R)-4-ΜΕΘΥΛ-3-[ΜΕΘΥΛ-(7Η-ΠΥΡΡΟΛΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-4-ΥΛ)-ΑΜΙΝΟ]-ΠΙΠΕΡΙΔΙΝΥΛ}-3-ΟΞΟ-ΠΡΟΠΙΟΝΙΤΡΙΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΩΝ ΠΡΩΤΕΪΝΗΣ
CY2017028C CY2017028I1 (el)	2001-05-31	2017-09-01	3-{(3R,4R)-4-ΜΕΘΥΛ-3-[ΜΕΘΥΛ-(7Η-ΠΥΡΡΟΛΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-4-ΥΛ)-ΑΜΙΝΟ]-ΠΙΠΕΡΙΔΙΝΥΛ}-3-ΟΞΟ-ΠΡΟΠΙΟΝΙΤΡΙΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΩΝ ΠΡΩΤΕΪΝΗΣ

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20121101069T CY1113322T1 (el)	2001-05-31	2012-11-09	3-{(3R,4R)-4-ΜΕΘΥΛ-3-[ΜΕΘΥΛ-(7Η-ΠΥΡΡΟΛΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-4-ΥΛ)-ΑΜΙΝΟ]-ΠΙΠΕΡΙΔΙΝΥΛ}-3-ΟΞΟ-ΠΡΟΠΙΟΝΙΤΡΙΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΩΝ ΠΡΩΤΕΪΝΗΣ

Country Status (52)

Country	Link
US (2)	US7301023B2 (el)
EP (3)	EP1392694A1 (el)
JP (1)	JP4381137B2 (el)
KR (5)	KR20040003037A (el)
CN (1)	CN1729192A (el)
AP (1)	AP1859A (el)
AR (2)	AR037321A1 (el)
AT (1)	ATE519741T1 (el)
AU (2)	AU2002304401C1 (el)
BE (1)	BE2017C032I2 (el)
BG (1)	BG66489B1 (el)
BR (1)	BR0209246A (el)
CA (1)	CA2448281C (el)
CL (1)	CL2008000762A1 (el)
CR (1)	CR10177A (el)
CU (1)	CU23337B7 (el)
CY (2)	CY1113322T1 (el)
CZ (1)	CZ304366B6 (el)
DK (1)	DK1666481T3 (el)
EA (2)	EA007251B1 (el)
EC (1)	ECSP034865A (el)
EE (1)	EE05332B1 (el)
ES (2)	ES2369226T3 (el)
FR (1)	FR17C1031I2 (el)
GE (1)	GEP20063784B (el)
GT (2)	GT200200100A (el)
HR (1)	HRP20030943B1 (el)
HU (2)	HU230876B1 (el)
IL (1)	IL158588A0 (el)
IS (1)	IS3023B (el)
LT (1)	LTC1666481I2 (el)
LU (1)	LUC00031I2 (el)
MA (1)	MA27029A1 (el)
MX (1)	MXPA03011062A (el)
MY (1)	MY129649A (el)
NL (1)	NL300887I2 (el)
NO (3)	NO328578B1 (el)
NZ (2)	NZ540332A (el)
OA (1)	OA12612A (el)
PA (1)	PA8546301A1 (el)
PE (1)	PE20030561A1 (el)
PL (2)	PL228155B1 (el)
PT (1)	PT1666481E (el)
RS (1)	RS52144B (el)
SI (1)	SI1666481T1 (el)
SK (2)	SK288199B6 (el)
TN (1)	TNSN03128A1 (el)
TW (2)	TWI310384B (el)
UA (1)	UA80093C2 (el)
UY (1)	UY27317A1 (el)
WO (1)	WO2002096909A1 (el)
ZA (1)	ZA200307982B (el)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
TR200201498T2 (tr)	1999-12-10	2003-01-21	Pfizer Products Inc.	Pirrolo [2,3-d] pirimidin bileşikleri.
CN100351253C (zh) *	2000-06-26	2007-11-28	辉瑞产品公司	作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
GT200200234A (es)	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es)	2002-07-29	2005-11-23	Rigel Pharmaceuticals Inc	Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
ATE402700T1 (de) *	2002-08-27	2008-08-15	Merck Patent Gmbh	Glycinamid-derivate als raf-kinase-hemmer
CA2507392A1 (en)	2002-11-26	2004-06-10	Pfizer Products Inc.	Method of treatment of transplant rejection
HRP20130602T1 (en)	2003-07-30	2013-07-31	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
EP1755680A1 (en) *	2004-05-03	2007-02-28	Novartis AG	Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
EP1768982A2 (en)	2004-06-29	2007-04-04	Amgen Inc.	Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
EP1797054A2 (en)	2004-08-02	2007-06-20	OSI Pharmaceuticals, Inc.	Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
WO2006056399A2 (en) *	2004-11-24	2006-06-01	Novartis Ag	Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AR054416A1 (es) *	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006133426A2 (en)	2005-06-08	2006-12-14	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2007007919A2 (en)	2005-07-14	2007-01-18	Astellas Pharma Inc.	Heterocyclic janus kinase 3 inhibitors
EP2251341A1 (en)	2005-07-14	2010-11-17	Astellas Pharma Inc.	Heterocyclic Janus kinase 3 inhibitors
ATE540952T1 (de)	2005-07-29	2012-01-15	Pfizer Prod Inc	Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese
EP2270014A1 (en)	2005-09-22	2011-01-05	Incyte Corporation	Azepine inhibitors of janus kinases
WO2007070514A1 (en)	2005-12-13	2007-06-21	Incyte Corporation	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP1991532B1 (en)	2006-02-24	2017-01-11	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
GB0605691D0 (en) *	2006-03-21	2006-05-03	Novartis Ag	Organic Compounds
US8513270B2 (en)	2006-12-22	2013-08-20	Incyte Corporation	Substituted heterocycles as Janus kinase inhibitors
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
SI3070090T1 (sl)	2007-06-13	2019-04-30	Incyte Holdings Corporation	Uporaba soli zaviralca Janus kinaze (R)-3-(4-(7H-pirolo (2,3-D)pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropannitrila
CN101743009A (zh) *	2007-07-11	2010-06-16	辉瑞大药厂	治疗干眼病的药物组合物和方法
CN102007124B (zh)	2008-02-15	2014-06-18	里格尔制药公司	嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途
CN102026999B (zh)	2008-03-11	2014-03-05	因塞特公司	作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
NZ589315A (en)	2008-04-16	2012-11-30	Portola Pharm Inc	2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
BRPI0910668A2 (pt)	2008-04-22	2019-09-24	Portola Pharmaceutiacals Inc	inibidores de proteína quinases
MX2011001259A (es) *	2008-08-01	2011-03-15	Biocryst Pharm Inc	Derivados de piperidina como inhibidores jak3.
RS53382B (en) *	2008-08-20	2014-10-31	Zoetis Llc	PIROL [2,3-D] PIRIMIDINE COMPOUNDS
CA2752150A1 (en) *	2009-02-11	2010-08-19	Reaction Biology Corp.	Selective kinase inhibitors
EP3026052A1 (en) *	2009-04-20	2016-06-01	Auspex Pharmaceuticals, Inc.	Preparation of deuterated piperidine inhibitors of janus kinase 3
SG176111A1 (en)	2009-05-22	2011-12-29	Incyte Corp	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
NZ596479A (en)	2009-05-22	2014-01-31	Incyte Corp	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2475667A1 (en) *	2009-09-10	2012-07-18	F. Hoffmann-La Roche AG	Inhibitors of jak
CN102596960B (zh)	2009-10-09	2016-01-20	因西特控股公司	3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
WO2011045702A1 (en)	2009-10-15	2011-04-21	Pfizer Inc.	Pyrrolo[2,3-d] pyrimidine compounds
WO2011075334A1 (en)	2009-12-18	2011-06-23	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine compounds
RU2012132278A (ru) *	2010-01-12	2014-02-20	Ф. Хоффманн-Ля Рош Аг	Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
JP2013518882A (ja)	2010-02-05	2013-05-23	ファイザー・インク	ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物
AU2011224484A1 (en)	2010-03-10	2012-09-27	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
MY161078A (en)	2010-05-21	2017-04-14	Incyte Holdings Corp	Topical formulation for a jak inhibitor
WO2012061428A2 (en)	2010-11-01	2012-05-10	Portola Pharmaceuticals, Inc.	Nicotinamides as jak kinase modulators
CA2818545C (en)	2010-11-19	2019-04-16	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
PE20140146A1 (es)	2010-11-19	2014-02-06	Incyte Corp	Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
EP2481411A1 (en)	2011-01-27	2012-08-01	Ratiopharm GmbH	Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en)	2011-01-27	2012-08-01	Ratiopharm GmbH	Pharmaceutical compositions comprising tasocitinib
MX357939B (es)	2011-02-18	2018-07-31	Novartis Pharma Ag	Terapia de combinacion de inhibidor de objetivo de rapamicina en mamifero/janus cinasa (mtor/jak).
EP2691395B1 (en)	2011-03-28	2017-08-30	ratiopharm GmbH	Processes for preparing tofacitinib salts
US9050342B2 (en)	2011-03-29	2015-06-09	Pfizer Inc.	Beneficial effects of combination therapy on cholesterol
EP2694512A1 (en) *	2011-04-08	2014-02-12	Pfizer Inc	Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
EP2524688B1 (en)	2011-05-11	2013-05-01	ratiopharm GmbH	Composition for modified release comprising ranolazine
WO2012177606A1 (en)	2011-06-20	2012-12-27	Incyte Corporation	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
JP2014521725A (ja)	2011-08-10	2014-08-28	ノバルティス・ファルマ・アクチェンゲゼルシャフト	ＪＡＫＰＩ３Ｋ／ｍＴＯＲ併用療法
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
AU2012340555B2 (en)	2011-11-23	2016-10-20	Portola Pharmaceuticals, Inc.	Pyrazine kinase inhibitors
US10821111B2 (en)	2011-11-30	2020-11-03	Emory University	Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
WO2013082476A1 (en) *	2011-11-30	2013-06-06	Emory University	Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
EP2791141B1 (en)	2011-12-15	2017-02-08	ratiopharm GmbH	Tofacitinib mono-tartrate salt
WO2013173720A1 (en)	2012-05-18	2013-11-21	Incyte Corporation	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN104837817B (zh)	2012-07-25	2017-03-22	力奇制药公司	制备3‑氨基‑哌啶化合物的合成路线
EP2903970A4 (en)	2012-10-08	2016-11-30	Portola Pharm Inc	SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
SMT202100436T1 (it)	2012-11-15	2021-09-14	Incyte Holdings Corp	Forme di dosaggio a rilascio prolungato di ruxolitinib
CN104955803B (zh) *	2012-11-30	2017-11-28	斯洛文尼亚莱柯制药股份有限公司	通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
US9481679B2 (en)	2012-12-17	2016-11-01	Sun Pharmaceutical Industries Limited	Process for the preparation of tofacitinib and intermediates thereof
EP2938616A4 (en)	2012-12-28	2016-06-15	Glenmark Pharmaceuticals Ltd	PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES
MD4735C1 (ro)	2013-02-22	2021-07-31	Pfizer Inc.	Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
UA121532C2 (uk)	2013-03-06	2020-06-10	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки при отриманні інгібітора jak
JP6041823B2 (ja)	2013-03-16	2016-12-14	ファイザー・インク	トファシチニブの経口持続放出剤形
US20140343034A1 (en)	2013-04-25	2014-11-20	Japan Tobacco Inc.	Skin barrier function improving agent
WO2014174073A1 (en)	2013-04-26	2014-10-30	Sandoz Ag	Sustained release formulations of tofacitinib
SG10201912203XA (en)	2013-08-07	2020-02-27	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
CN104513248B (zh) *	2013-09-30	2019-05-24	重庆医药工业研究院有限责任公司	一种托法替尼中间体的纯化方法
PT3077395T (pt)	2013-12-05	2018-01-03	Pfizer	Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas
EP2994454B1 (en)	2013-12-09	2019-03-06	Unichem Laboratories Limited	An improved process for the preparation of (3r,4r)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine
CA2881262A1 (en)	2014-02-06	2015-08-06	Prabhudas Bodhuri	Solid forms of tofacitinib salts
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016024185A1 (en)	2014-08-12	2016-02-18	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US10617690B2 (en) *	2015-01-20	2020-04-14	Wuxi Fortune Pharmaceutical Co., Ltd	JAK inhibitor
WO2016133317A1 (ko) *	2015-02-17	2016-08-25	(주)아모레퍼시픽	Ｎ-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
CN104761556B (zh) *	2015-03-21	2017-06-23	河北国龙制药有限公司	托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
EP3078665A1 (en)	2015-04-10	2016-10-12	OLON S.p.A.	Efficient method for the preparation of tofacitinib citrate
PL3290418T3 (pl)	2015-04-29	2019-11-29	Wuxi Fortune Pharmaceutical Co Ltd	Inhibitory kinaz janusowych (jak)
JP6761815B2 (ja)	2015-05-01	2020-09-30	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、ピロロ［２，３−ｂ］ピリジニルアクリルアミド、およびそのエポキシド
JP6564473B2 (ja)	2015-05-29	2019-08-21	无▲錫▼福祈制▲薬▼有限公司ＷｕｘｉＦｏｒｔｕｎｅＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ	Ｊａｎｕｓキナーゼ阻害剤
KR101964546B1 (ko) *	2015-07-27	2019-04-01	유니켐 레버러토리스 리미티드	토파시티닙 경구 붕해 정제
KR101771219B1 (ko) *	2015-08-21	2017-09-05	양지화학 주식회사	야누스 키나제 1 선택적 억제제 및 그 의약 용도
US10045981B2 (en)	2015-11-24	2018-08-14	Jakpharm, Llc	Selective kinase inhibitors
CN105348287A (zh) *	2015-11-30	2016-02-24	宁波立华制药有限公司	一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) *	2016-01-04	2023-08-10	(주)아모레퍼시픽	극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
US20190083609A1 (en)	2016-01-18	2019-03-21	Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh)	Tofacitinib as vaccination immune modulator
EP3950691A1 (en)	2016-06-30	2022-02-09	Daewoong Pharmaceutical Co., Ltd.	Pyrazolopyrimidine derivatives as kinase inhibitor
CN106831538B (zh) *	2017-01-22	2019-06-25	苏州楚凯药业有限公司	托法替尼中间体的制备方法
KR102398659B1 (ko)	2017-03-17	2022-05-16	주식회사 대웅제약	카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) *	2017-10-23	2018-01-19	上海博悦生物科技有限公司	一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko)	2017-11-30	2020-02-19	보령제약 주식회사	토파시티닙을 포함하는 약제학적 조성물
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
KR102577241B1 (ko)	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
BR112020013141B1 (pt)	2017-12-28	2022-03-15	Daewoong Pharmaceutical Co., Ltd	Compostos de óxi-fluoropiperidina como inibidores de quinase, composição farmacêutica compreendendo os mesmos e seu uso na prevenção ou no tratamento de doenças inflamatórias, doenças autoimunes, doenças proliferativas ou doenças hiperproliferativas e doenças imunomediadas, cânceres, tumores
PL3746429T3 (pl)	2018-01-30	2022-06-20	Incyte Corporation	Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu)
CA3089108A1 (en) *	2018-01-31	2019-08-08	Twi Pharmaceuticals, Inc.	Topical formulations comprising tofacitinib
US12161748B2 (en)	2018-01-31	2024-12-10	Twi Biotechnology, Inc.	Topical formulations comprising tofacitinib
PE20210402A1 (es)	2018-03-30	2021-03-02	Incyte Corp	Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
KR102131107B1 (ko) *	2019-01-15	2020-07-07	주식회사 다산제약	3-아미노-피페리딘 화합물의 신규한 제조 방법
NL2022471B1 (en)	2019-01-29	2020-08-18	Vationpharma B V	Solid state forms of oclacitinib
WO2020183295A1 (en)	2019-03-13	2020-09-17	Intas Pharmaceuticals Ltd.	Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
EP3946606B1 (en)	2019-03-27	2025-01-01	Insilico Medicine IP Limited	Bicyclic jak inhibitors and uses thereof
ES2977277T3 (es) *	2019-04-05	2024-08-21	Yuhan Corp	Procesos para preparar (3R,4R)-1-bencil-n,4-dimetilpiperidin-3-amina o una de sus sales y procesos para preparar tofacitinib mediante el uso de la misma
MX2022005882A (es)	2019-11-14	2022-06-14	Pfizer	Combinaciones de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2- il)metoxi)-7-metoxiisoquinolin-6-carboxamida y formas de dosis orales.
WO2021107590A1 (ko)	2019-11-25	2021-06-03	주식회사 대웅제약	신규한 트리아졸로피리딘 유도체 및 이를 포함하는 약학 조성물
WO2021198980A1 (en)	2020-04-04	2021-10-07	Pfizer Inc.	Methods of treating coronavirus disease 2019
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
US20240166651A1 (en) *	2021-03-15	2024-05-23	Chiesi Farmaceutici S.P.A.	Heterocyclic derivatives as janus kinase inhibitors
EP4180042A1 (en)	2021-11-15	2023-05-17	Sanovel Ilac Sanayi Ve Ticaret A.S.	A film coated tablet comprising micronized tofacitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8403224A (nl)	1984-10-24	1986-05-16	Oce Andeno Bv	Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6136595A (en)	1993-07-29	2000-10-24	St. Jude Children's Research Hospital	Jak kinases and regulations of cytokine signal transduction
US5389509A (en)	1993-10-04	1995-02-14	Eastman Kodak Company	Ultrathin high chloride tabular grain emulsions
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0682027B1 (de)	1994-05-03	1997-10-15	Novartis AG	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JPH07330732A (ja) *	1994-06-10	1995-12-19	Kyorin Pharmaceut Co Ltd	光学活性な３−アミノ−１−ベンジルピペリジン誘導体
US6136596A (en) *	1995-05-19	2000-10-24	University Of Massachusetts	Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
WO1996040142A1 (en)	1995-06-07	1996-12-19	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
ES2167586T3 (es)	1995-07-05	2002-05-16	Du Pont	Pirimidinonas fungicidas.
EA001428B1 (ru)	1995-07-06	2001-02-26	Новартис Аг	Пирролопиримидины и фармацевтические композиции, включающие эти соединения
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
CA2209598C (en)	1995-11-14	2005-06-07	Pharmacia & Upjohn Spa	Aryl and heteroaryl purine compounds
DE69712745T2 (de)	1996-01-23	2002-10-31	Novartis Ag, Basel	Pyrrolopyrimidinen und verfahren zu deren herstellung
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en)	1996-02-29	1996-05-01	Pharmacia Spa	4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en)	1996-03-06	1997-09-22	Novartis Ag	7-alkyl-pyrrolo{2,3-d}pyrimidines
WO1997049706A1 (en)	1996-06-25	1997-12-31	Novartis Ag	SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
ATE231148T1 (de)	1996-07-13	2003-02-15	Glaxo Group Ltd	Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
CA2262421C (en)	1996-08-23	2007-10-02	Novartis Ag	Substituted pyrrolopyrimidines and processes for their preparation
JP2000505109A (ja)	1996-11-27	2000-04-25	ファイザー・インク	縮合二環式ピリミジン誘導体
BR9807305A (pt)	1997-02-05	2000-05-02	Warner Lambert Co	Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
EP0972197A1 (en)	1997-03-24	2000-01-19	PHARMACIA & UPJOHN COMPANY	Method for identifying inhibitors of jak2/cytokine receptor binding
EP1068206A1 (en)	1998-04-02	2001-01-17	Neurogen Corporation	Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors
KR20010052450A (ko)	1998-05-28	2001-06-25	파커 휴우즈 인스티튜트	뇌종양 치료를 위한 퀴나졸린
PA8474101A1 (es) *	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
ES2219018T3 (es)	1998-06-19	2004-11-16	Pfizer Products Inc.	Compuestos de pirrolo(2,3-d)pirimidina.
JP2004504259A (ja)	1998-06-30	2004-02-12	パーカー　ヒューズ　インスティテュート	Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法
KR20010089171A (ko)	1998-08-21	2001-09-29	추후제출	퀴나졸린 유도체
US6080747A (en)	1999-03-05	2000-06-27	Hughes Institute	JAK-3 inhibitors for treating allergic disorders
TR200201498T2 (tr) *	1999-12-10	2003-01-21	Pfizer Products Inc.	Pirrolo [2,3-d] pirimidin bileşikleri.
CN100351253C (zh) *	2000-06-26	2007-11-28	辉瑞产品公司	作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
GT200200234A (es) *	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
EP1768982A2 (en) *	2004-06-29	2007-04-04	Amgen Inc.	Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity

2002
- 2002-05-23 US US10/154,699 patent/US7301023B2/en not_active Expired - Lifetime
- 2002-05-29 KR KR10-2003-7015681A patent/KR20040003037A/ko not_active Ceased
- 2002-05-29 KR KR1020067025590A patent/KR20060133117A/ko not_active Ceased
- 2002-05-29 KR KR1020087018519A patent/KR100926875B1/ko not_active Expired - Lifetime
- 2002-05-29 SI SI200231004T patent/SI1666481T1/sl unknown
- 2002-05-29 HU HUP0400152A patent/HU230876B1/hu active Protection Beyond IP Right Term
- 2002-05-29 PL PL409305A patent/PL228155B1/pl unknown
- 2002-05-29 KR KR1020077025832A patent/KR100868814B1/ko not_active Expired - Lifetime
- 2002-05-29 HR HR20030943A patent/HRP20030943B1/xx not_active IP Right Cessation
- 2002-05-29 CA CA002448281A patent/CA2448281C/en not_active Expired - Lifetime
- 2002-05-29 DK DK05015454.1T patent/DK1666481T3/da active
- 2002-05-29 EA EA200301193A patent/EA007251B1/ru active Protection Beyond IP Right Term
- 2002-05-29 ES ES05015461T patent/ES2369226T3/es not_active Expired - Lifetime
- 2002-05-29 EA EA200600575A patent/EA012666B1/ru active Protection Beyond IP Right Term
- 2002-05-29 AT AT05015461T patent/ATE519741T1/de not_active IP Right Cessation
- 2002-05-29 GE GE5361A patent/GEP20063784B/en unknown
- 2002-05-29 AU AU2002304401A patent/AU2002304401C1/en not_active Expired
- 2002-05-29 PE PE2002000452A patent/PE20030561A1/es not_active Application Discontinuation
- 2002-05-29 OA OA1200300308A patent/OA12612A/en unknown
- 2002-05-29 TN TNPCT/IB2002/001905A patent/TNSN03128A1/fr unknown
- 2002-05-29 TW TW091111480A patent/TWI310384B/zh active
- 2002-05-29 NZ NZ540332A patent/NZ540332A/en not_active IP Right Cessation
- 2002-05-29 CN CNA028108175A patent/CN1729192A/zh active Pending
- 2002-05-29 SK SK1465-2003A patent/SK288199B6/sk unknown
- 2002-05-29 EP EP02733058A patent/EP1392694A1/en not_active Withdrawn
- 2002-05-29 EP EP05015461A patent/EP1609781B1/en not_active Expired - Lifetime
- 2002-05-29 MX MXPA03011062A patent/MXPA03011062A/es active IP Right Grant
- 2002-05-29 KR KR1020067001821A patent/KR100869409B1/ko not_active Expired - Lifetime
- 2002-05-29 JP JP2003500088A patent/JP4381137B2/ja not_active Expired - Lifetime
- 2002-05-29 SK SK50033-2011A patent/SK288192B6/sk active Protection Beyond IP Right Term
- 2002-05-29 NZ NZ530380A patent/NZ530380A/en not_active IP Right Cessation
- 2002-05-29 CZ CZ2003-3260A patent/CZ304366B6/cs not_active IP Right Cessation
- 2002-05-29 EP EP05015454.1A patent/EP1666481B9/en not_active Expired - Lifetime
- 2002-05-29 IL IL15858802A patent/IL158588A0/xx active IP Right Grant
- 2002-05-29 RS YU92303A patent/RS52144B/en unknown
- 2002-05-29 WO PCT/IB2002/001905 patent/WO2002096909A1/en active Application Filing
- 2002-05-29 ES ES05015454T patent/ES2393385T3/es not_active Expired - Lifetime
- 2002-05-29 PL PL02367945A patent/PL367945A1/xx unknown
- 2002-05-29 PT PT50154541T patent/PT1666481E/pt unknown
- 2002-05-29 BR BR0209246-8A patent/BR0209246A/pt not_active Application Discontinuation
- 2002-05-29 EE EEP200300594A patent/EE05332B1/xx active Protection Beyond IP Right Term
- 2002-05-29 UA UA20031110841A patent/UA80093C2/uk unknown
- 2002-05-29 TW TW092133699A patent/TWI316061B/zh not_active IP Right Cessation
- 2002-05-30 GT GT200200100A patent/GT200200100A/es unknown
- 2002-05-30 AR ARP020102017A patent/AR037321A1/es not_active Application Discontinuation
- 2002-05-30 MY MYPI20021988A patent/MY129649A/en unknown
- 2002-05-30 UY UY27317A patent/UY27317A1/es not_active Application Discontinuation
- 2002-05-30 PA PA20028546301A patent/PA8546301A1/es unknown
- 2002-05-30 GT GT200200100AK patent/GT200200100AA/es unknown
- 2002-05-31 AP APAP/P/2002/002550A patent/AP1859A/en active
2003
- 2003-10-13 CU CU20030229A patent/CU23337B7/es not_active IP Right Cessation
- 2003-10-13 IS IS6993A patent/IS3023B/is unknown
- 2003-10-14 ZA ZA200307982A patent/ZA200307982B/en unknown
- 2003-11-21 MA MA27410A patent/MA27029A1/fr unknown
- 2003-11-24 NO NO20035201A patent/NO328578B1/no not_active IP Right Cessation
- 2003-11-26 EC EC2003004865A patent/ECSP034865A/es unknown
- 2003-11-27 BG BG108389A patent/BG66489B1/bg unknown
2004
- 2004-05-07 AR ARP040101561A patent/AR045680A2/es unknown
- 2004-06-16 US US10/869,101 patent/US7432370B2/en not_active Expired - Lifetime
2008
- 2008-03-14 CL CL200800762A patent/CL2008000762A1/es unknown
- 2008-07-16 AU AU2008203170A patent/AU2008203170B2/en active Active
- 2008-07-24 CR CR10177A patent/CR10177A/es unknown
2009
- 2009-10-13 NO NO20093135A patent/NO20093135L/no not_active Application Discontinuation
2012
- 2012-11-09 CY CY20121101069T patent/CY1113322T1/el unknown
2017
- 2017-08-02 NL NL300887C patent/NL300887I2/nl unknown
- 2017-08-08 LT LTPA2017025C patent/LTC1666481I2/lt unknown
- 2017-08-09 LU LU00031C patent/LUC00031I2/fr unknown
- 2017-08-17 BE BE2017C032C patent/BE2017C032I2/fr unknown
- 2017-09-01 CY CY2017028C patent/CY2017028I1/el unknown
- 2017-09-04 FR FR17C1031C patent/FR17C1031I2/fr active Active
- 2017-09-08 NO NO2017047C patent/NO2017047I1/no unknown
2019
- 2019-02-19 HU HUS1900008C patent/HUS1900008I1/hu unknown

Also Published As

Publication number	Publication date
ES2393385T3 (es)	2012-12-20
HUP0400152A2 (en)	2007-07-30
AR037321A1 (es)	2004-11-03
AU2008203170A1 (en)	2008-08-07
US7301023B2 (en)	2007-11-27
CA2448281C (en)	2009-05-05
BE2017C032I2 (el)	2021-07-19
CR10177A (es)	2008-08-19
EP1666481B9 (en)	2013-05-01
UY27317A1 (es)	2003-02-28
BG66489B1 (bg)	2015-05-29
CA2448281A1 (en)	2002-12-05
CY2017028I2 (el)	2018-02-14
EP1609781B1 (en)	2011-08-10
MXPA03011062A (es)	2004-03-19
PL409305A1 (pl)	2014-12-22
PL367945A1 (en)	2005-03-07
RS52144B (en)	2012-08-31
CN1729192A (zh)	2006-02-01
EP1392694A1 (en)	2004-03-03
KR100926875B1 (ko)	2009-11-16
NO20035201D0 (no)	2003-11-24
EP1609781A1 (en)	2005-12-28
DK1666481T3 (da)	2012-10-15
UA80093C2 (uk)	2007-08-27
SK288199B6 (sk)	2014-06-03
EA200600575A1 (ru)	2006-08-25
KR100868814B1 (ko)	2008-11-14
AP1859A (en)	2008-07-02
ZA200307982B (en)	2004-10-14
EP1666481A2 (en)	2006-06-07
NZ530380A (en)	2005-08-26
GEP20063784B (en)	2006-04-10
HRP20030943A2 (en)	2005-08-31
EP1666481B1 (en)	2012-09-19
EE200300594A (et)	2004-04-15
TW200413370A (en)	2004-08-01
SK14652003A3 (sk)	2004-05-04
IS6993A (is)	2003-10-13
LUC00031I2 (el)	2017-10-11
US20030073719A1 (en)	2003-04-17
CZ304366B6 (cs)	2014-04-02
NL300887I2 (nl)	2017-08-31
JP2004534047A (ja)	2004-11-11
PL228155B1 (pl)	2018-02-28
NO328578B1 (no)	2010-03-22
NO2017047I1 (no)	2017-09-08
EP1666481A3 (en)	2006-11-29
SK288192B6 (sk)	2014-06-03
KR20040003037A (ko)	2004-01-07
OA12612A (en)	2006-06-09
TWI316061B (en)	2009-10-21
HU230876B1 (hu)	2018-11-29
NO20035201L (no)	2003-11-24
TNSN03128A1 (fr)	2005-12-23
NO20093135L (no)	2003-11-24
US7432370B2 (en)	2008-10-07
PT1666481E (pt)	2012-12-03
ATE519741T1 (de)	2011-08-15
JP4381137B2 (ja)	2009-12-09
SI1666481T1 (sl)	2012-11-30
MA27029A1 (fr)	2004-12-20
HUS1900008I1 (hu)	2020-02-28
LUC00031I1 (el)	2017-08-10
LTC1666481I2 (lt)	2018-06-25
ES2369226T3 (es)	2011-11-28
KR20080083028A (ko)	2008-09-12
HRP20030943B1 (hr)	2011-11-30
EE05332B1 (et)	2010-08-16
FR17C1031I1 (fr)	2017-10-13
KR20060133117A (ko)	2006-12-22
FR17C1031I2 (fr)	2018-11-02
AU2008203170B2 (en)	2009-06-18
CU23337B7 (es)	2009-01-20
IL158588A0 (en)	2004-05-12
PE20030561A1 (es)	2003-06-23
NZ540332A (en)	2007-05-31
YU92303A (sh)	2006-08-17
LTPA2017025I1 (lt)	2017-09-11
AU2002304401B2 (en)	2008-04-17
KR100869409B1 (ko)	2008-11-21
IS3023B (is)	2020-08-15
CZ20033260A3 (en)	2004-03-17
HUP0400152A3 (en)	2012-12-28
PA8546301A1 (es)	2003-05-14
WO2002096909A1 (en)	2002-12-05
TWI310384B (en)	2009-06-01
CL2008000762A1 (es)	2008-07-04
GT200200100A (es)	2003-02-11
GT200200100AA (es)	2007-07-06
AU2002304401C1 (en)	2009-03-05
MY129649A (en)	2007-04-30
CY1113322T1 (el)	2016-06-22
ECSP034865A (es)	2004-01-28
KR20080002931A (ko)	2008-01-04
BR0209246A (pt)	2004-06-15
BG108389A (bg)	2005-01-31
EA012666B1 (ru)	2009-12-30
KR20060014459A (ko)	2006-02-15
AP2002002550A0 (en)	2002-06-30
AR045680A2 (es)	2005-11-09
US20040229923A1 (en)	2004-11-18
EA200301193A1 (ru)	2004-04-29
EA007251B1 (ru)	2006-08-25

Publication	Publication Date	Title
CY2017028I1 (el)	2018-02-14	3-{(3R,4R)-4-ΜΕΘΥΛ-3-[ΜΕΘΥΛ-(7Η-ΠΥΡΡΟΛΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-4-ΥΛ)-ΑΜΙΝΟ]-ΠΙΠΕΡΙΔΙΝΥΛ}-3-ΟΞΟ-ΠΡΟΠΙΟΝΙΤΡΙΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΩΝ ΠΡΩΤΕΪΝΗΣ
CA2469350A1 (en)	2003-06-12	3-{4-methyl-3[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt
EE200200506A (et)	2004-02-16	5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
DK1235830T3 (da)	2004-03-29	Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
HUP0400300A3 (en)	2010-12-28	Pyrrolopyrimidines as protein kinase inhibitors
NO20031190D0 (no)	2003-03-14	Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20032670L (no)	2003-08-15	Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20041887L (no)	2004-05-07	Benzomidazoler anvendelige som proteinkinase-inhibitorer
AU2003254053A8 (en)	2004-02-09	Pyrazolopyrimidines as protein kinase inhibitors
NO20035728D0 (no)	2003-12-19	Pyrrolopyrimidiner som proteinkinaseinhibitorer
DK1317448T4 (da)	2011-05-30	Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer